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Abstract Insulin-like growth factors are involved in the
paracrine growth regulation of human breast tumor cells. IGF2
is imprinted in most tissues, and shows expression of the paternal
allele only. To investigate whether disruption of this monoallelic
IGF2 expression is involved in breast cancer development, a
series of primary tumors and adjacent, histologically normal,
breast tissue samples, as well as matched primary in vitro
fibroblast cultures were studied. Biallelic expression (partial) of
IGF2 was found in the majority of in vivo samples, and
corresponding fibroblast cultures, while monoallelic expression
was found in a normal breast sample. In contrast, H19, a closely
apposed, but reciprocally imprinted gene, assumed to be
regulated by a common control element, showed retention of
monoallelic H19 expression in all in vivo and in the majority of in
vitro samples. These data indicate that IGF2, but not H19, is
prone to loss of imprinting in breast cancer.
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1. Introduction
A complex bi-directional interaction between malignant ep-
ithelial cells and surrounding stromal tissue appears to be
crucial in the development and progression of breast cancer.
In addition to the frequently detected genetic alterations in
breast tumor cells [1], stromal cells within or immediately
adjacent to the neoplastic site have been shown to display
phenotypical changes [2,3]. Although a variety of di¡erent
growth factors are probably involved [4], insulin-like growth
factors (IGFs) secreted by ¢broblasts have been shown to be,
at least partly, responsible for the induced breast tumor cell
proliferation in vitro [5]. Two di¡erent IGFs have been dis-
tinguished, i.e. IGF1 and IGF2, and numerous studies have
shown the involvement of these two factors in growth regu-
lation of breast cancer and other malignancies [6,7].
Interestingly, IGF2 has been shown to be imprinted, an
epigenetic phenomenon describing the di¡erential expression
of alleles based on their parental origin ([8,9] for review), and
this gene is suggested to be part of an imprinted domain
together with the H19 gene [10]. While IGF2 is preferentially
expressed in most tissues from the paternal allele [11], H19 is
expressed only from the maternal allele [12]. Regulation of
IGF2 and H19 expression has been suggested to be closely
linked and to involve a common enhancer element [10,13].
Coordinated allele-speci¢c expression of both IGF2 and
H19 appears to be important for normal embryonal develop-
ment ([14] for review). Furthermore, loss of imprinting (LOI)
and/or structural chromosomal alteration in the IGF2/H19
locus has been suggested to correlate with development of a
number of both childhood and adult tumors, for example,
sporadic Wilms’ tumors, bladder, cervical, lung and prostate
carcinomas and testicular germ cell tumors [9,15]. In addition,
constitutional loss of IGF2 imprinting has been demonstrated
in in vitro cultures of skin ¢broblast derived from Beckwith-
Wiedemann syndrome patients, which are prone to develop
cancer [16].
In this study we investigated the presence of LOI of IGF2
and H19 in breast cancer. For this purpose we analyzed the
allele-speci¢c expression of these genes by a reverse transcrip-
tion-polymerase chain reaction (RT-PCR) approach, in a ser-
ies of matched primary tumor and adjacent, histologically
normal, breast tissue samples as well as primary in vitro ¢-
broblast cultures established from these tissues.
2. Materials and methods
2.1. Cell culture
Primary ¢broblast cultures were established from breast carcinomas
and adjacent histologically normal breast tissue (n = 8), and propa-
gated as described previously [5].
2.2. RNA extraction and cDNA synthesis
Total RNA was isolated from subcon£uent primary ¢broblast cul-
tures (at passage 5^8) and cryosections from corresponding frozen
tissue using RNA STAT-60 according to the protocol of the supplier
(Tel-Test ‘B’). Parallel cryosections were used for histology. cDNA
was synthesized using MMLV reverse transcriptase (Gibco-BRL, Bre-
da, Netherlands).
2.3. IGF2 and H19 gene expression
The expression of the IGF2 and H19 genes, in both the in vitro and
in vivo samples, was determined by PCR ampli¢cation of the gener-
ated cDNA, using gene speci¢c primer combinations spanning intron
sequences. The following primers were used: IGF2: IG-4a, 5P-CCT-
GGAGACGTACTGTGCTACC-3P and IG-8, 5P-TGGGTAGAGCA-
ATCAGGGGAC-3P (annealing at 62‡C); H19: HN-6, 5P-CTTTCA-
TGTTGTGGGTTCTGGGA-3P and HN-7, 5P-CCAGGTCTCCAG-
CTGGGGTG-3P (annealing at 64‡C). Negative controls were used
in every PCR assay and included samples without reverse transcrip-
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tase (RNA control), and samples where cDNA was omitted (water
control).
2.4. Detection of IGF2 and H19 polymorphism
Genomic DNA was extracted from frozen tissue using standard
techniques. The IGF2 allelic pattern for each patient was determined
using the ApaI polymorphism located in the untranslated region of
exon 9; primers: IG-for, 5P-CTTGGACTTTGAGTCAAATTGG-3P
and IG-5, 5P-GGGTCGTGCCAATTACATTTCAT-3P, annealing
temp. 56‡C [17]. The polymorphic sites AviII or RsaI, both located
within exon 5 and only 40 bp apart, were analyzed for the H19 gene
(primers: HN-19, 5P-TGACTGAGGAATCGGCTCTGGAAG-3P
and HN-20, 5P-CGGTCGGAGCTTCCAGACTAG-3P, annealing
temp. 64‡C). The polymerase chain reaction (PCR), subsequent diges-
tion and analysis were performed as previously described [18].
2.5. Allele-speci¢c gene expression
The allele-speci¢c IGF2 and H19 expression of the informative
samples was determined, in at least two independently isolated
RNA preparations of each sample, using the primer combinations
IG-for/IG-5 (IGF2) and HN19/HN20 (H19). To avoid interference
of contaminating DNA in the allele-speci¢c IGF2 expression analysis
the RNA was DNase-treated, prior to the cDNA synthesis. Therefore,
RNA was incubated with 20 units RNase-free DNase (Boehringer-
Mannheim) for 30 min at 37‡C. The samples were subsequently phe-
nol/chloroform extracted and ethanol precipitated. Each resuspended
RNA sample was evenly split and incubated with or without reverse
transcriptase (RT) as describe above. In the subsequent PCR the
additional negative (minus RT) control was included for each sample.
Only those DNase-treated RNAs, irrefutably shown to be devoid of
DNA, were used for the subsequent analysis of the IGF2 allele-spe-
ci¢c expression. The obtained cDNA-PCR products were digested to
completion using the required restriction enzyme and analyzed on a
2% Nusieve agarose ethidium bromide gel.
3. Results and discussion
The clinical and pathological data of the eight cases in-
cluded in this study are summarized in Table 1. All patients
were older than 35 years, with an average age of 54.4. All
tumors were primary breast cancers, and surgically removed.
Only patient #8 was pretreated with chemotherapy prior to
surgery. Six cases were diagnosed as ductal carcinomas, and
two (cases #2 and #4) as mixed, containing both ductal and
lobular carcinoma elements. Three patients had a positive
axillary lymph node status. The estrogen and progesterone
receptor status varied between 0^546, and 0^218 fmol/mg pro-
tein, respectively.
All primary tumors and adjacent, histologically normal,
breast tissues in vivo as well as in the derived in vitro ¢bro-
blast cultures showed expression using RT-PCR of both IGF2
and H19 (results not shown). Subsequently, we studied the
imprinted status, i.e. mono-/biallelic expression, of these
genes. Analysis of the H19-informative cases, using the poly-
morphic AviII site, revealed monoallelic expression in all ¢ve
primary tumor and all four available adjacent histologically
normal tissues in vivo (see Fig. 1A and Table 2). In the three
patients shown to be also informative for the RsaI site, the
monoallelic H19 expression in vivo was con¢rmed. Similarly,
H19 imprinting was sustained in most of the in vitro ¢bro-
blast cultures. In one case (case #8), however, both the tumor
and normal tissue derived from in vitro ¢broblast cultures
displayed biallelic H19 expression, although the correspond-
ing in vivo tumor tissue showed monoallelic expression. In
addition to the digestion analysis, the results were veri¢ed
by direct sequencing. As shown in Fig. 1B, both the allele
with the AviII-restriction site (-TGCGCA-) and the digestion
resistant polymorphic speci¢c allelic sequence (-TGTGCA-)
were detected. Because of the fact that the in vivo sample
predominantly consisted of tumor cells, the monoallelic H19
expression detected in this sample could merely re£ect the
expression in tumor cells, rather than in the stromal ¢bro-
blasts. Indeed, H19 expression has been observed in both
epithelial and stromal cells in breast tumor and adjacent nor-
mal tissue using in situ hybridization [19]. Although we can-
not exclude a culture speci¢c induced LOI, similar to an ob-
servation by Eversole-Cire et al. [20], the phenomenon of
biallelic H19 expression in the ¢broblast cultures is obviously
not a general in vitro induced e¡ect and thus indicates that
the in vivo imprinting status is mostly maintained in vitro.
The observed in vitro biallelic H19 expression could be related
to the chemotherapeutic treatment this patient received before
surgical removal of the cancer. Overall our data suggest that
LOI of H19 is not a general phenomenon in the development
and/or progression of breast cancer, con¢rming a recent study
by Yballe et al. [21], in contrast to the ¢nding in other cancers
([9,15] for review).
Our study has furthermore revealed an intriguing allelic
switch of H19 expression in case #1 (see Fig. 1A and Table
2). While monoallelic expression of the AviII digested allele
was detected in the in vivo tumor tissue, only the undigested
allele was shown to be expressed in the adjacent normal tissue
and the ¢broblast cultures in vitro. This suggests that the
tumor cell population has switched H19 expression to the
otherwise silent allele. Monoallelic expression of the normally
silent H19 allele has recently also been observed in cervical
carcinomas [22]. In normal adult cerebellum tissue a similar
switch has been described by Zhang et al. [23]. In addition,
their study revealed biallelic H19 expression in lung tissue,
while in the other tissues monoallelic H19 expression was
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Table 1
Summary of the clinical and pathological data of the breast tumor cases
Case Age (years) Histology (carcinoma) Tumor sizeb Nodal status ER/PRc Follow up
#1 51 Ductal T1 3 76/218 Alive, relapse after 6 years
#2 66 Mixeda T1 + 43/28 Alive, NEDd after 6.5 years
#3 60 Ductal T2 3 5/0 Dead of disease after 4 years
#4 53 Ductal T2 3 37/5 Alive, relapse after 6 years
#5 42 Mixed T2 3 0/17 Dead of disease after 4.5 years
#6 36 Ductal T1 3 4/0 Dead of disease after 1.5 years
#7 79 Ductal T1 + 546/6 Dead of disease after 2.5 years
#8 48 Ductal T3/4 + 71/190 Alive, NED after 3.5 years
aContaining both ductal and lobular elements.
bT1 = 6 2 cm, T2 = 2^5 cm, T3/4 = s 5 cm.
cEstrogen and progesterone receptor levels in fmol/mg protein.
dNo evidence of disease.
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detected. The observed variability of H19 allele-speci¢c ex-
pression in this patient thus supports a previously suggested
cell type or tissue speci¢c regulatory mechanism.
In contrast to H19, our analysis of the IGF2 informative
cases showed partial LOI in the majority of in vivo samples,
derived not only from the tumor but also from the adjacent,
histologically normal tissues (see Fig. 2A and Table 3), as
revealed by the presence of both the ApaI-resistant A-allele
and the ApaI-sensitive B-allele after digestion of the RT-PCR
products. Remarkable, LOI appears to be con¢ned to the
IGF2 gene, as was especially illustrated by cases #5 and #6,
which were also informative for H19 (see Fig. 1A and Table
2). In only one of the informative patients (case #4) mono-
allelic IGF2 expression was detected in the primary tumor and
adjacent normal tissue. Interestingly, this patient was still
alive after 6 years of diagnosis of the initial tumor, although
a relapse was found, while the other three patients died of
their disease within 4.5 years after initial diagnosis. To deter-
mine whether this is a signi¢cant observation requires a more
extended analysis. However, the data suggest that expression
of IGF2 is regulated in a similar fashion in both tissue sites.
Interestingly, the allele with the restriction site (the B-allele)
was most predominant, while an equal ratio of both alleles
was observed in the respective DNA samples analyzed (results
not shown). Variable levels of relaxation have also been de-
scribed by others [24], probably re£ecting heterogeneity of the
samples under investigation. To con¢rm that the observed A-
allele is genuinely present, the RT-PCR products were ana-
lyzed by direct sequencing. This indeed revealed the presence
of the expected, ApaI-resistant (-GGACCC-) allelic sequence
(not shown). In addition, the restriction resistant fragments,
isolated from the gel after the initial digest analysis, were
reampli¢ed and ApaI digested. Again, as expected, these prod-
ucts remained undigested (results not shown) con¢rming the
previous data. Unfortunately, the parental origin of the alleles
could not be determined due to lack of parental DNA.
An IGF2 allele-speci¢c expression pattern, similar to the in
vivo samples, was observed for most corresponding in vitro
samples (Fig. 2A and Table 3). As indicated for H19, this
again suggests that the in vivo imprinting status is generally
maintained in early passage primary ¢broblast cultures.
Although LOI in cultured cells can occur after multiple pas-
sages, maintenance of genomic imprinting in early passage
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Table 2
Allele speci¢c H19 expression in the informative primary breast tu-
mor, corresponding adjacent histologically normal tissue, and
matched ¢broblast in vitro cultures
Case Tissue In vivo In vitro
AviII RsaI AviII RsaI
#1 Normal A B A B
Tumor B A A B
#2 Normal B A B A
Tumor B A B A
#5 Normal A B A B
Tumor A B A B
#6 Normal B NIa B NI
Tumor B NI B NI
#8 Normal NAb NA A/Bc NI
Tumor A NI A/B NI
aNot informative.
bNot available.
cBalanced expression of the A and B allele.
Table 3
Allele-speci¢c IGF2 expression in the informative primary breast tu-
mor, corresponding adjacent histologically normal tissue, and
matched ¢broblast in vitro cultures
Case Tissue In vivo In vitro
#4 Normal A A
Tumor A B
#5 Normal aBa aB
Tumor aB A
#6 Normal aB aB
Tumor aB aB
#7 Normal NAb ABc
Tumor aB AB
aExpression of A-allele between 10^25% of total level.
bNot available.
cBalanced expression of the A and B allele.
Fig. 1. A: Results of the allele-speci¢c expression analysis of H19 as determined by RT-PCR in samples of breast tumor patients informative
for the AviII polymorphism. Shown are the AviII restriction endonuclease digests of the ampli¢cation products (generated by the HN19/HN20
primers) from primary tumor tissues (T) and adjacent normal breast tissues (N) in vivo and the derived ¢broblast in vitro cultures. Note the
monoallelic expression of H19 in all samples, except the ¢broblast cultures of case #8. B: Part of the H19 sequence, as obtained by direct se-
quencing of the RT-PCR product from the in vitro tumor sample from case #8. The arrow indicates the presence of ampli¢cation products
representative for both alleles, demonstrated by identi¢cation of a thymidine (T) and a cytosine (C) within the AviII restriction recognition site
(-TGCGCA-).
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cultures has previously been described [16,25]. In addition,
monoallelic IGF2 expression was found, as expected, in a
¢broblast culture derived from a cosmetic reduction mammo-
plasty (see Fig. 2B). Our data thus suggest that, in contrast to
H19, LOI of IGF2 is involved in breast cancer development
and/or progression. While relaxation of IGF2 imprinting in
breast tumor, as shown here, has been reported by others
[21,24,26], our study further indicates the presence of epige-
netically modi¢ed cells in the adjacent normal tissue. Biallelic
expression of IGF2 in not only the tumor cells but also the
associated normal tissue has also been reported by others in
breast [22], and in other tumor types, including those of the
prostate and Wilms’ tumor [17,27]. This indicates that besides
phenotypical changes, as previously described [2,3], the stro-
mal cells within, or immediately adjacent to the cancer also
show changes in the allelic expression pattern of IGF2. This
does not seem to be in£uenced by clinical and/or pathological
parameters.
An intriguing result was obtained upon the IGF2 analysis
of one of the tumor tissue derived ¢broblast cultures (case
#5). Although the original tissue in vivo was shown to express
both alleles, the corresponding in vitro sample displayed
monoallelic IGF2 expression. The in vivo preferentially ex-
pressed allele was shown to be fully silent in the in vitro
sample. Furthermore, the allelic switch observed was shown
to be con¢ned to the IGF2 gene, because the H19 allele-spe-
ci¢c expression was not altered in this case (see Table 2). Our
data, speci¢cally those from cases #5 and 6, informative for
both IGF2 and H19, thus suggest independent transcriptional
regulation of these two genes in breast tissue, in contrast to a
proposed regionally controlled regulation of IGF2 and H19
expression [13]. Although this ‘enhancer competition model’ is
supported by the observations of several studies in mice ([9]
for review), also less compatible data are emerging suggesting,
like our study, that the allele-speci¢c transcriptional regula-
tion of these two genes is not as closely linked as previously
assumed [22,28,29].
Another remarkable example of the versatility in the regu-
lation of IGF2 expression was displayed in one of the in vitro
tumor tissue ¢broblast samples (case #4). While the ¢broblast
culture revealed monoallelic expression of the B-allele, the
corresponding in vivo tumor sample showed expression of
only the A-allele. Subsequent allelotypic analysis of ¢broblast
DNA showed that this was due to a complete loss of the non-
expressed A-allele in this culture (not shown).
In summary, we have presented data showing that the al-
lelic expression pattern of IGF2 and H19 is regulated in a
similar fashion in malignant and adjacent histologically nor-
mal breast tissue. Our data furthermore indicate that IGF2,
but not H19, is prone to loss of imprinting in breast cancer.
Extended studies are required, however, to further substanti-
ate these ¢ndings.
Acknowledgements: We like to thank Dr. B. Tycko (Department of
Pathology, Divisions of Oncology and Neuropathology, Columbia
University, New York, USA), Dr. T. Moulton (Department of Pedi-
atrics, Division of Pediatric Hematology-Oncology, Columbia Univer-
sity, New York, USA) and Dr. A.J.M.H. Verkerk (Lab. for Exp.
Patho-Oncology, Daniel den Hoed Cancer Center) for their informa-
tion concerning the H19 polymorphic AviII location and sequence.
This study was supported by the Dutch Cancer Society Grants
DDHK 91-15 and DDHK 94-867.
References
[1] BieØche, I. and Lidereau, R. (1995) Genes Chromosomes Cancer
14, 227^251.
[2] Garin-Chesa, P., Old, L.J. and Rettig, W.J. (1990) Proc. Natl.
Acad. Sci. USA 87, 7235^7239.
[3] Kaczmarek, J., Castellani, P., Nicolo, G., Spina, B., Allemanni,
G. and Zardi, L. (1994) Int. J. Cancer 58, 11^16.
[4] Cullen, K.J., Smith, H.S., Hill, S., Rosen, N. and Lippman, M.E.
(1991) Cancer Res. 51, 4978^4985.
[5] van Roozendaal, C.E.P., Klijn, J.G.M., van Ooijen, B., Claassen,
C., Eggermont, A.M.M., Henzen-Logmans, S.C. and Foekens,
J.A. (1996) Int. J. Cancer 65, 120^125.
[6] Macaulay, V.M. (1992) Br. J. Cancer 65, 311^320.
[7] Ellis, M.J.C., Singer, C., Hornby, A., Rasmussen, A. and Cullen,
K.J. (1994) Breast Cancer Res. Treat. 31, 249^261.
[8] Franklin, G.C., Adam, G.I.R. and Ohlsson, R. (1996) Placenta
17, 3^14.
[9] Looijenga, L.H.J., Verkerk, A.J.M.H., de Groot, N., Hochberg,
FEBS 20970 19-10-98
Fig. 2. A: Results of the allele-speci¢c expression analysis of IGF2 as determined by RT-PCR in in vivo tissue samples and matched in vitro ¢-
broblast cultures of breast tumor patients informative for the ApaI polymorphism. Shown are the ApaI restriction digest of the ampli¢cation
products (generated by the IG-for/IG-5 primers) from primary tumor tissue (T) and adjacent normal breast tissue (N) in vivo and the derived
in vitro ¢broblast cultures. Note the (partial) biallelic expression in all cases, except case #4. B: Results of allele-speci¢c IGF2 expression in an
ApaI informative in vitro ¢broblast culture established from a cosmetic reduction mammaplasty tissue sample (CRM = cosmetic reduction mam-
maplasty). Shown are the ApaI restriction digest of the PCR-ampli¢ed ¢broblast DNA and cDNA products (generated by the IG-for/IG-5
primers). Note the monoallelic expression of the B allele.
C.E.P. van Roozendaal et al./FEBS Letters 437 (1998) 107^111110
A.A. and Oosterhuis, J.W. (1997) Mol. Reprod. Dev. 46, 419^
439.
[10] Zemel, S., Bartolomei, M.S. and Tilghman, S.M. (1992) Nat.
Genet. 2, 61^65.
[11] Giannoukakis, N., Deal, C., Paquette, J., Goodyer, C.G. and
Polychronakos, C. (1993) Nat. Genet. 4, 98^101.
[12] Zhang, Y. and Tycko, B. (1992) Nat. Genet. 1, 40^44.
[13] Bartolomei, M.S., Webber, A.L., Brunkow, M.E. and Tilghman,
S.M. (1993) Genes Dev. 7, 1663^1673.
[14] Latham, K.E., McGrath, J. and Solter, D. (1995) Int. Rev. Cytol.
160, 53^98.
[15] Brenton, J.D., Viville, S. and Surani, M.A. (1995) Cancer Sur-
veys 25, 161^171.
[16] Weksberg, R., Shen, D.R., Fei, Y.L., Song, Q.L. and Squire, J.
(1993) Nat. Genet. 5, 143^150.
[17] Jarrard, D.F., Bussemakers, M.J.G., Bova, G.S. and Isaacs, W.B.
(1996) Clin. Cancer Res. 1, 1471^1478.
[18] Verkerk, A.J.M.H., Ariel, I., Dekker, M.C., Schneider, T., van
Gurp, R.J.H.L.M., Gillis, A.J.M., Oosterhuis, J.W., Hochberg,
A.A. and Looijenga, L.H.J. (1997) Oncogene 14, 95^107.
[19] Dugimont, T., Curgy, J.-J., Wernert, N., Delobelle, A., Raes,
M.-B., Joubel, A., Stehelin, D. and Coll, J. (1995) Biol. Cell
85, 117^124.
[20] Eversole-Cire, P., Ferguson-Smith, A.C., Surani, M.A. and
Jones, P.A. (1995) Cell Growth Di¡er. 6, 337^345.
[21] Yballe, C.M., Vu, T.H. and Ho¡man, A.R. (1996) J. Clin. En-
docrinol. Metab. 81, 1607^1612.
[22] Douc-Rasy, S., Barrois, M., Fogel, S., Ahomadegbe, J.C., Stehe-
lin, D., Coll, J. and Riou, G. (1996) Oncogene 12, 423^430.
[23] Zhang, Y., Shields, T., Crenshaw, T., Hao, Y., Moulton, T. and
Tycko, B. (1993) Am. J. Hum. Genet. 53, 113^124.
[24] McCann, A.H., Miller, N., O’Meara, A., Pedersen, I., Keogh, K.,
Gorey, T. and Dervan, P.A. (1996) Hum. Mol. Genet. 5, 1123^
1127.
[25] Hu, J.-F., Vu, T.H. and Ho¡man, A.R. (1998) J. Biol. Chem.
272, 20715^20720.
[26] Wu, H.-K., Squire, J.A., Catzavelos, C.G. and Weksberg, R.
(1997) Biochem. Biophys. Res. Commun. 235, 123^129.
[27] Okamoto, K., Morison, I.M., Taniguchi, T. and Reeve, A.E.
(1997) Proc. Natl. Acad. Sci. USA 94, 5367^5371.
[28] Rainier, S., Dobry, C.J. and Feinberg, A.P. (1995) Cancer Res.
55, 1836^1838.
[29] Uyeno, S., Aoki, Y., Nata, M., Sagisaka, K., Kayama, T., Yosh-
imoto, T. and Ono, T. (1996) Cancer Res. 56, 5356^5359.
FEBS 20970 19-10-98
C.E.P. van Roozendaal et al./FEBS Letters 437 (1998) 107^111 111
